Literature DB >> 19405550

Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

Mukesh Patel1.   

Abstract

Meticillin-resistant Staphylococcus aureus (MRSA) is an important cause of infection, particularly in hospitalized patients and those with significant healthcare exposure. In recent years, epidemic community-associated MRSA (CA-MRSA) infections occurring in patients without healthcare risk factors have become more frequent. The most common manifestation of CA-MRSA infection is skin and soft tissue infection, although necrotizing pneumonia, sepsis and osteoarticular infections can occur. CA-MRSA strains have become endemic in many communities and are genetically distinct from previously identified MRSA strains. CA-MRSA may be more capable colonizers of humans and more virulent than other S. aureus strains. Specific mechanisms of pathogenicity have not been elucidated, but several factors have been proposed as responsible for the virulence of CA-MRSA, including the Panton-Valentine leukocidin, phenol-soluble modulins and type I arginine catabolic mobile element. The movement of CA-MRSA strains into the nosocomial setting limits the utility of using clinical risk factors alone to designate community- or healthcare-associated status. Identification of unique genetic characteristics and genotyping are valuable tools for MRSA epidemiological studies. Although the optimum pharmacological therapy for CA-MRSA infections has not been determined, many CA-MRSA strains remain broadly susceptible to several non-beta-lactam antibacterial agents. Empirical antibacterial therapy should include an MRSA-active agent, particularly in areas where CA-MRSA is endemic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19405550     DOI: 10.2165/00003495-200969060-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  193 in total

1.  Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus.

Authors:  Binh An Diep; Heather A Carleton; Richard F Chang; George F Sensabaugh; Francoise Perdreau-Remington
Journal:  J Infect Dis       Date:  2006-04-21       Impact factor: 5.226

2.  Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic.

Authors:  Christopher J Graber; Mark A Jacobson; Francoise Perdreau-Remington; Henry F Chambers; Binh An Diep
Journal:  J Acquir Immune Defic Syndr       Date:  2008-10-01       Impact factor: 3.731

3.  The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

Authors:  E J Ellis-Grosse; T Babinchak; N Dartois; G Rose; E Loh
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

4.  Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-04-13       Impact factor: 17.586

5.  Cavernous sinus thrombosis and meningitis from community-acquired methicillin-resistant Staphylococcus aureus infection.

Authors:  W J Munckhof; A Krishnan; P Kruger; D Looke
Journal:  Intern Med J       Date:  2008-04       Impact factor: 2.048

6.  Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin.

Authors:  Philippe Dufour; Yves Gillet; Michèle Bes; Gerard Lina; François Vandenesch; Daniel Floret; Jerome Etienne; Hervé Richet
Journal:  Clin Infect Dis       Date:  2002-09-03       Impact factor: 9.079

7.  Intrapulmonary penetration of linezolid.

Authors:  David Honeybourne; Caroline Tobin; Gail Jevons; Jenny Andrews; Richard Wise
Journal:  J Antimicrob Chemother       Date:  2003-05-13       Impact factor: 5.790

8.  Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection.

Authors:  N Markowitz; E L Quinn; L D Saravolatz
Journal:  Ann Intern Med       Date:  1992-09-01       Impact factor: 25.391

9.  Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection.

Authors:  Priya M Rajendran; David Young; Toby Maurer; Henry Chambers; Francoise Perdreau-Remington; Peter Ro; Hobart Harris
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

10.  Methamphetamine use and methicillin-resistant Staphylococcus aureus skin infections.

Authors:  Adam L Cohen; Carrie Shuler; Sigrid McAllister; Gregory E Fosheim; Michael G Brown; Debra Abercrombie; Karen Anderson; Linda K McDougal; Cherie Drenzek; Katie Arnold; Daniel Jernigan; Rachel Gorwitz
Journal:  Emerg Infect Dis       Date:  2007-11       Impact factor: 6.883

View more
  17 in total

1.  High prevalence of ST121 in community-associated methicillin-susceptible Staphylococcus aureus lineages responsible for skin and soft tissue infections in Portuguese children.

Authors:  T Conceição; M Aires-de-Sousa; N Pona; M J Brito; C Barradas; R Coelho; T Sardinha; L Sancho; G de Sousa; M do Céu Machado; H de Lencastre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-11-03       Impact factor: 3.267

2.  Staphylococcus aureus YoeB homologues inhibit translation initiation.

Authors:  Satoshi Yoshizumi; Yonglong Zhang; Yoshihiro Yamaguchi; Liang Chen; Barry N Kreiswirth; Masayori Inouye
Journal:  J Bacteriol       Date:  2009-07-06       Impact factor: 3.490

3.  Methicillin-resistant Staphylococcus aureus colonization among health care workers in a downtown emergency department in Toronto, Ontario.

Authors:  Gregory Saito; Jessica Thom; Yanliang Wei; Piraveina Gnanasuntharam; Pirasanya Gnanasuntharam; Nathan Kreiswirth; Barbara Willey; Michelle Loftus; Catherine Varner; Vanessa Porter; Allison McGeer; Bjug Borgundvaag
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

4.  Bacterial cultures, rapid strep test, and antibiotic treatment in infected hard-to-heal ulcers in primary care.

Authors:  Rut F Oien; Nina Akesson
Journal:  Scand J Prim Health Care       Date:  2012-10-10       Impact factor: 2.581

Review 5.  Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci.

Authors:  Ana Maria Rivera; Helen W Boucher
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

6.  Activity of the streptogramin antibiotic etamycin against methicillin-resistant Staphylococcus aureus.

Authors:  Nina M Haste; Varahenage R Perera; Katherine N Maloney; Dan N Tran; Paul Jensen; William Fenical; Victor Nizet; Mary E Hensler
Journal:  J Antibiot (Tokyo)       Date:  2010-03-26       Impact factor: 2.649

7.  Telavancin.

Authors:  Katherine A Lyseng-Williamson; Stephanie K A Blick
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Methicillin-resistant Staphylococcus aureus: an overview for manual therapists().

Authors:  Bart N Green; Claire D Johnson; Jonathon Todd Egan; Michael Rosenthal; Erin A Griffith; Marion Willard Evans
Journal:  J Chiropr Med       Date:  2012-03

9.  An unexpected diagnosis of methicillin-resistant Staphylococcus aureus septic arthritis.

Authors:  Tanujan Thangarajah; Timothy J Neal; Thomas D Kennedy
Journal:  Orthop Rev (Pavia)       Date:  2009-10-10

10.  Methicillin-resistant Staphylococcus aureus nasal colonization among adult patients visiting emergency department in a medical center in Taiwan.

Authors:  Sheng-Yun Lu; Fang-Yu Chang; Ching-Chung Cheng; Keong-Diong Lee; Yhu-Chering Huang
Journal:  PLoS One       Date:  2011-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.